Biomea Fusion, Inc. (BMEA)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Michael J. M. Hitchcock Ph.D. | Interim CEO & Director | 56.5k | -- | 1950 |
| Mr. Ramses M. Erdtmann | Co-Founder, President, COO & Director | 489.6k | -- | 1963 |
| Mr. Heow Tan | Chief Technology & Quality Officer | -- | -- | 1959 |
| Ms. Naomi Cretcher | Chief People Officer | -- | -- | -- |
| Dr. Thorsten Kirschberg Ph.D. | Executive Vice President of Chemistry | -- | -- | 1970 |
| Dr. Stephan Morris M.D. | Chief Development Officer | -- | -- | -- |
| Mr. Ravi Upasani Ph.D. | Executive Vice President of Intellectual Property | -- | -- | -- |
| Dr. Juan Pablo Frias M.D. | Chief Medical Officer | 492.25k | -- | -- |
| Caroline Perez- Dupont J.D. | Senior Vice President of Contracts | -- | -- | -- |
Biomea Fusion, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 79
Description
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. It's lead product candidate is icovamenib, is designed to be a bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair, it is used for the treatment of menin regulated or dependent diseases such as type 1 and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Corporate Governance
Upcoming Events
July 31, 2025 at 8:00 PM UTC - August 14, 2025 at 8:00 PM UTC
Biomea Fusion, Inc. Earnings Date